StageZero Life Sciences Ltd
14.3.2022 16:27:02 CET | ACCESS Newswire | Press release
This release replaces and corrects the release that was issued earlier this morning
TORONTO, ON / ACCESSWIRE / March 14, 2022 / StageZero Life Sciences, Ltd. (TSX:SZLS) (OTCQB:SZLSF) ("StageZero" or the "Company"), a vertically integrated healthcare company devoted to improving the early detection and management of cancer and other chronic diseases through leading-edge molecular diagnostics and clinical interventions, announces that the Care Oncology Clinic service and COC Protocol is now available to patients living in Europe. This builds on the availability of the service and program in the UK, the US and Canada.
Care Oncology Clinic provides high quality outpatient treatment in an independent setting with experienced UK and European specialists. The Clinic offers adjunctive treatments that may complement or enhance standard-of-care cancer management. Its patented COC Protocol incorporates a multifaceted approach, supported by peer-reviewed scientific studies, which highlight the potential of certain treatments to target the specific energy requirements of cancer cells, impacting their ability to grow and multiply.
Care is personalized for individual needs and patients receive regular monitoring and support. The service is available both in person at premises in Harley Street, London, UK, and remotely via telemedicine.
"Europe, with a population of approximately 750 million, and a healthcare focus that matches our early detection and management of cancer approach, is a natural extension to our successful Clinics in the UK. We are pleased to continue expanding the availability of our programs geographically and this builds upon our corporate long term growth initiatives of broadening, deepening and expanding our offerings" said James Howard-Tripp, Chairman and CEO of StageZero.
About StageZero Life Sciences, Ltd.
StageZero Life Sciences, Ltd. is a vertically integrated healthcare company dedicated to improving the early detection and management of cancer and other chronic diseases through next-generation diagnostics and unique telehealth programs that provide clinical interventions to assist patients who currently have cancer (COC Protocol) as well as help patients reduce the risk of developing late-stage disease (AVRT™).
The Company's next generation test, Aristotle®, is the first ever mRNA multi-cancer panel for simultaneously screening for multiple cancers from a single sample of blood with high sensitivity and specificity for each cancer. Aristotle® uses mRNA technology to identify the molecular signatures of multiple cancer types and is built on the Company's patented technology platform, the Sentinel Principle. This underlying technology has been validated in more than 9,000 patients and used by more than 100,000 patients in North America.
The Care Oncology Clinic offers a supervised treatment regimen (the COC Protocol) for people diagnosed with cancer of any type or stage. Developed by scientists and oncologists, the COC Protocol is intended for adjunctive administration alongside standard-of-care cancer therapy. It is an individualized therapeutic approach which seeks to simultaneously target multiple metabolic cancer pathways. The aim is to restrict cancer cell energy supply and use, which may make it more difficult overall for cancer cells to survive, grow and adapt to changing conditions in the body. As a result, such cells can potentially become more vulnerable to attack from cell-killing therapies such as radiotherapy and chemotherapy. Its patented COC Protocol incorporates a multifaceted approach, supported by peer-reviewed scientific studies, which highlight the potential of certain treatments to target the specific energy requirements of cancer cells, impacting their ability to grow and multiply.
AVRT is a Physician-Led, telehealth program for identifying and managing the early warning signs of cancer and chronic disease. Our program includes: a comprehensive online health evaluation; blood tests to measure markers of inflammation and metabolism; an in-depth initial physician consultation; regular physician follow-up appointments and interval screening.
Aristotle®, as well as additional cancer diagnostics (ColonSentry®, BreastSentry™, and the Prostate Health Index) are processed at the Company's clinical laboratory, StageZero Life Sciences, Inc., a CAP accredited and CLIA certified high-complexity reference laboratory in Richmond, Virginia. In addition, the Company is also leveraging its specialty in polymerase chain reaction (PCR) testing to provide COVID-19 PCR testing (swab and saliva) and Antibody Testing (blood analysis).
StageZero Life Sciences trades on the Toronto Stock exchange under the symbol SZLS and on the OTCQB under the symbol SZLSF.
Forward-Looking Statements
This press release contains forward-looking statements identified by words such as "expects", "will" and similar expressions, which reflect the Company's current expectations regarding future events. The forward-looking statements involve risks and uncertainties that could cause the Company's actual events to differ materially from those projected herein. Investors should consult the Company's ongoing quarterly filings and annual reports for additional information on risks and uncertainties relating to these forward-looking statements. The reader is cautioned not to rely on these forward-looking statements. The Company disclaims any obligation to update these forward-looking statements, except as required by law.
For further information please contact:
Investor Relations
Rebecca Greco
1-855-420-7140 ext. 1838
rgreco@stagezerols.com
SOURCE: StageZero Life Sciences
View source version on accesswire.com:
https://www.accesswire.com/692951/CORRECTING-AND-REPLACING-StageZero-Life-Sciences-Announces-Availability-of-COC-Protocol-in-Europe
To view this piece of content from www.accesswire.com, please give your consent at the top of this page.
About ACCESS Newswire
Subscribe to releases from ACCESS Newswire
Subscribe to all the latest releases from ACCESS Newswire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from ACCESS Newswire
Polaris Announces Execution of Mixed Investment Agreement for the Three Mexico Projects7.7.2026 13:50:00 CEST | Press release
TORONTO, ON / ACCESS Newswire / July 7, 2026 / Polaris Renewable Energy Inc. (TSX:PIF) ("Polaris" or the "Company") is pleased to announce that, further to its press release dated June 8, 2026, it has reached another important milestone in the development of its three renewable energy projects selected under Mexico's Comisión Federal de Electricidad ("CFE") Mixed Development Program (the "Mixed Program"). On July 3, 2026, Polaris, through its Mexican project structure, executed the Mixed Investment Agreement (Contrato de Inversión Mixta or "CIM") with the fiduciary trustee, Banca Mifel, S.A., Institucion de Banca Multiple, Grupo Financiero Mifel, acting on behalf of CFE. The CIM establishes the contractual 30-year framework governing the joint participation of Polaris and CFE in the development, financing, construction, ownership and operation of the three selected projects, including the applicable governance, economic and corporate arrangements. The CIM includes the key information a
Oxford University Press Comes to Simply Piano7.7.2026 10:00:00 CEST | Press release
Content from OUP's acclaimed piano method is now available to millions of Simply Piano learners worldwide NEW YORK, NY / ACCESS Newswire / July 7, 2026 / Simply, the leading digital platform for creative hobbies, today announced an agreement to bring content from Oxford University Press' (OUP) piano method to Simply Piano. This expands Simply Piano's offering and marks a step forward in its mission to make the pursuit of creative hobbies simple and fun for all. Simply Piano users around the world will gain access to an expanded library of high-quality, curated sheet music spanning OUP's works including Piano Time and Tunes for Ten Fingers, all within the app's interactive learning environment. The integration expands Simply Piano's sheet music library across genres, complementing its step-by-step courses and real-time feedback tools. "Access to songs people love is one of the strongest drivers of learning," said Yuval Kaminka, CEO & co-founder of Simply. "Working with OUP allows us to
AM Technical Solutions Acquires Sequence, Inc., Expanding Life Sciences Engineering and Commissioning, Qualification, and Validation (CQV) Capabilities7.7.2026 07:00:00 CEST | Press release
KILDARE, IRELAND / ACCESS Newswire / July 7, 2026 / AM Technical Solutions (AM), a global architecture, engineering, construction, and commissioning firm specializing in high-technology markets, announces the acquisition of Sequence, Inc., a leading engineering firm specializing in Process Design, Commissioning, Qualification, and Validation (CQV) solutions for life sciences and related high-tech industries. Sequence, headquartered in Morrisville, North Carolina, brings deep expertise in CQV, Computer System Validation (CSV), IT/OT integration, operational readiness, and life sciences engineering excellence. Their cross-functional approach to process engineering and facility startup has earned them a strong track record accelerating time to market for pharmaceutical and biopharmaceutical clients across the full project lifecycle -- from conceptual design through licensure and commercial operations. This acquisition deepens AM's existing Engineering and CQV capabilities with proven team
Crossmint Secures Payment Institution and MiCA Authorization, Completing a Full-Stack EU Regulatory Stack for Stablecoin Payments3.7.2026 21:00:00 CEST | Press release
With Authorization as a Crypto-Asset Service Provider Under MiCA and Payment Institution Under PSD2, Crossmint Now Operates Under Both of the EU's Core Frameworks for Stablecoin Infrastructure, Giving Enterprise Fintechs One Regulated Provider to Hold Stablecoins and Move Them as Payments MADRID, ES / ACCESS Newswire / July 3, 2026 / Crossmint has been authorized as a Payment Institution (PI) by the Bank of Spain under the EU's Payment Services Directive (PSD2). Earlier this year, Crossmint received MiCA class 2 authorization from Spain's CNMV, establishing complete authorization to operate as a crypto-asset service provider across the EU. After completing the required conditions, Crossmint has now successfully been fully registered as a CASP with CNMV, which allows passporting across all 27 EU member states. PSD2 authorization is the natural expansion of that compliance footprint, enabling stablecoins to be used as a means of payment under EU payments law. "Crossmint's mission is to b
Polaris Renewable Energy Announces Q2 2026 Investor Call Details3.7.2026 19:30:00 CEST | Press release
TORONTO, ON / ACCESS Newswire / July 3, 2026 / Polaris Renewable Energy Inc. (TSX:PIF) ("Polaris" or the "Company") is pleased to announce it will be holding its Earnings Conference Call and Webcast to report its Q2 2026 Earnings Results on Thursday, July 30th, 2026, at 10:00 am EST. To listen to the call, please dial Toll Free 1 888-506-0062 or International Toll-Free Number 973-528-0011 entry code 503447 or URL: https://www.webcaster5.com/Webcast/Page/2773/53517 A digital recording of the earnings call will be available for replay two hours after the call's completion. Replay Call Information: Toronto: 1 877-481-4010, Passcode: 53517 International (toll-free): 1 919-882-2331, Passcode: 53517 Encore Replay Expiration Date: August 13, 2026 About Polaris Renewable Energy Inc. Polaris Renewable Energy Inc. is a Canadian publicly traded company engaged in the acquisition, development, and operation of renewable energy projects in Latin America and the Caribbean. We are a high-performing a
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom